AARD Stock Forecast & Price Target

Aardvark Therapeutics is facing a temporary hold on their Phase 3 clinical trial for their promising product candidate, ARD-101, due to observed QRS prolongation effects in a healthy volunteer study. However, management has expressed confidence in resolving this issue in a timely manner and the FDA has been positive in their guidance. Additionally, preliminary exposure-response modeling suggests the potential for lower doses to fall below the QRS effect threshold, providing flexibility in the trial design.

Aardvark Therapeutics is facing potential safety concerns with its lead product candidate ARD-101, as evidenced by the voluntary pause in dosing in the pivotal HERO trial. Additionally, the company's projected cash runway only extends until 2027E, leaving limited time for potential revenue from ARD-101's expected approval and launch in 2029 to offset expenses. Furthermore, the company's focus on targeting Bitter Taste Receptors for hunger-associated conditions may face stiff competition from established GLP-1 drugs and other innovative treatments for obesity.